These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37190983)

  • 61. Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.
    Teng MM; Chen SY; Yang B; Wang Y; Han RY; An MN; Dong YL; You HS
    Cancer Med; 2021 Sep; 10(18):6344-6353. PubMed ID: 34382361
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis.
    Brito ABC; Camandaroba MPG; de Lima VCC
    Thorac Cancer; 2021 Apr; 12(7):1058-1066. PubMed ID: 33586297
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.
    Cui W; Luo Q; Sun SL; Xu JL; Gu H
    Recenti Prog Med; 2022 Dec; 113(12):722-732. PubMed ID: 36420848
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis.
    Ye J; Ji X; Dennis PA; Abdullah H; Mukhopadhyay P
    Clin Pharmacol Ther; 2020 Dec; 108(6):1274-1288. PubMed ID: 32564368
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Immunotherapy for Esophageal and Gastric Cancer.
    Kelly RJ
    Am Soc Clin Oncol Educ Book; 2017; 37():292-300. PubMed ID: 28561677
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
    Széles Á; Fazekas T; Váncsa S; Váradi M; Kovács PT; Krafft U; Grünwald V; Hadaschik B; Csizmarik A; Hegyi P; Váradi A; Nyirády P; Szarvas T
    Cancer Immunol Immunother; 2023 May; 72(5):1061-1073. PubMed ID: 36385210
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy.
    Huang TC; Liang CW; Li YI; Guo JC; Lin CC; Chen YJ; Cheng AL; Hsu CH
    J Cancer Res Clin Oncol; 2022 Jul; 148(7):1803-1811. PubMed ID: 34432128
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
    Kim H; Lim DH; Kwon YS; Kim MA; Park KU
    Anticancer Res; 2023 May; 43(5):2343-2349. PubMed ID: 37097676
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
    Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
    JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.
    Zeng Z; Yang B; Liao Z
    Future Oncol; 2021 Apr; 17(12):1553-1569. PubMed ID: 33397136
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy and safety of PD-1/PD-L1 inhibitor combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis.
    Liu BW; Shang QX; Yang YS; Chen LQ
    Front Oncol; 2023; 13():1077675. PubMed ID: 37114136
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy and safety of anti-PD-1/PD-L1 in combination with chemotherapy or not as first-line treatment for advanced non-small cell lung cancer: A systematic review and network meta-analysis.
    Wang L; Yang Y; Yu J; Zhang S; Li X; Wu X; Nie X; Liu W; Zhang P; Li Y; Li A; Ai B
    Thorac Cancer; 2022 Feb; 13(3):322-337. PubMed ID: 34907661
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma.
    Koemans WJ; Chalabi M; van Sandick JW; van Dieren JM; Kodach LL
    Cancer Lett; 2019 Feb; 442():279-286. PubMed ID: 30419350
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
    Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
    EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies.
    Chen M; Li C; Sun M; Li Y; Sun X
    Front Immunol; 2022; 13():1043517. PubMed ID: 36505480
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Immune checkpoint inhibitors alone vs immune checkpoint inhibitors-combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis.
    Wang Y; Han H; Zhang F; Lv T; Zhan P; Ye M; Song Y; Liu H
    Br J Cancer; 2022 Sep; 127(5):948-956. PubMed ID: 35641819
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for esophageal cancer treatment: A systematic review and meta-analysis.
    Noori M; Yousefi AM; Zali MR; Bashash D
    Front Oncol; 2022; 12():1021859. PubMed ID: 36591463
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis.
    Cheng Y; Wang C; Wang Y; Dai L
    Future Oncol; 2022 Jan; 18(2):261-273. PubMed ID: 34874185
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Advancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkers.
    Cetin B; Wabl CA; Gumusay O
    Immunotherapy; 2023 Aug; 15(12):945-962. PubMed ID: 37291863
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy.
    Ma X; Ding Y; Qian J; Wan M; Li N; Mao C; Xiao C; Jiang H; Zheng Y; Wu L; Chen X; Xu N
    Curr Oncol; 2022 Nov; 29(11):8937-8954. PubMed ID: 36421355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.